Drugs / SYS6055
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT07493174 | Apr 2026 → Apr 2028 expected | B-cell neoplasm | Institute of Hematology & Blood Diseases Hospital, China | Not yet recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT07476066 | Mar 2026 → Mar 2029 expected | aggressive B-cell non-Hodgkin lymphoma | Beijing Kangchuanglian Biopharmaceutical Technology Research Co., Ltd | Not yet recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2026-01-29 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Regulatory VOLUNTARY ANNOUNCEMENT - SYS6055 INJECTION OBTAINS CLINICAL TRIAL APPROVAL IN CHINA irasia.com ↗ |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2026-01-29 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | VOLUNTARY ANNOUNCEMENT - SYS6055 INJECTION OBTAINS CLINICAL TRIAL APPROVAL IN CHINA irasia.com ↗ |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SYS6055 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07476066 ↗ |